{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:34:28Z","timestamp":1792668868053,"version":"4.5.0"},"reference-count":69,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN 154285"],"award-info":[{"award-number":["FDN 154285"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["NHLBI: PO1HL144457"],"award-info":[{"award-number":["NHLBI: PO1HL144457"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Manuscript background and aim<\/jats:title>\n                    <jats:p>The diagnosis and clinical care of patients with von Willebrand disease (VWD) has continued to evolve since the characterization of the von Willebrand factor (VWF) gene in 1985. This condition is almost certainly the most common inherited bleeding disorder, and the major symptomatic burden of the disease is experienced by females during their reproductive years. Diagnosis relies on the identification of a personal and family history of excessive mucocutaneous bleeding, and laboratory features consistent with quantitative and\/or qualitative abnormalities of VWF. This review focuses on three aspects of VWD management, with current updates and a look into the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Manuscript themes<\/jats:title>\n                    <jats:p>First, we will address the role of genetics in the diagnosis and possible therapies for VWD. With current technologies, VWD genetic diagnosis is usually confined to the confirmation of type 2 subtypes of the disease and type 3 VWD analysis for family planning. While type 3 VWD is a potential candidate for the application of gene therapy, no treatments are currently close to entering the clinic. Second, the peri\u2010procedural management of patients with VWD remains an important element of care. The choice of product, its dose and schedule all require careful consideration depending upon the type and disruptive nature of the planned procedure. Lastly, in addition to gene therapy, several other novel therapeutic interventions are also being developed for bleeding and prophylaxis in VWD. These include a VWF aptamer interfering with VWF clearance and bioengineered forms of VWF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.14970","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T02:21:50Z","timestamp":1710382910000},"page":"103-111","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Diagnosis and treatment of von Willebrand disease in 2024 and beyond"],"prefix":"10.1111","volume":"30","author":[{"given":"Paula","family":"James","sequence":"first","affiliation":[{"name":"Departments of Medicine and Pathology and Molecular Medicine Queen's University  Kingston Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Leebeek","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6795","authenticated-orcid":false,"given":"Caterina","family":"Casari","sequence":"additional","affiliation":[{"name":"University Paris\u2010Saclay, INSERM, Hemostasis Inflammation Thrombosis HITH U1176  Le Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-6312","authenticated-orcid":false,"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine Queen's University  Kingston Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03661.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003265"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021105"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-020784"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673681"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.6.1691.1691"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.869156"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034532"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3874428"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.19.6394"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112974"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00215a036"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13938"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1722862"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3605"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-00218-6"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010643"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1715442"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15131"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13881"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003264"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.11.042"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005666"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13451"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13488"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040403"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13064"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02588.x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02583.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003891"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049493"},{"issue":"3","key":"e_1_2_10_34_1","first-page":"387","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease","volume":"88","author":"Makris M","year":"2002","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14313"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02758.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12498"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-008-0253-7"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.07.023"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12664"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12586"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018534"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12254"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-872291"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz157"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.683"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14518"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000368"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14725"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629873"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014810"},{"issue":"23","key":"e_1_2_10_52_1","first-page":"1","article-title":"Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open\u2010label, randomised, crossover trial","volume":"3026","author":"Ragni MV","year":"2023","journal-title":"Lancet Haematol"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14209"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000656"},{"key":"e_1_2_10_56_1","first-page":"786","article-title":"Treatment with emicizumab leads to clinical improvement in a type 3 von Willebrand disease patient with inhibitor suffering from left ankle arthropathy","volume":"4","author":"Sigaud M","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102530"},{"key":"e_1_2_10_58_1","article-title":"Prophylactic emicizumab in children and adults with type 3 von Willebrand disease","volume":"68","author":"Vo K","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14491"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279948"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007805"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170245"},{"issue":"1","key":"e_1_2_10_63_1","first-page":"18","article-title":"HMB\u2010001 \u2010 a novel bispecific antibody with potential for subcutaneous prophylactic treatment of multiple bleeding disorders\u2014initial focus on Glanzmann Thrombasthenia","volume":"28","author":"Gandhi PS","year":"2022","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_10_64_1","first-page":"103","article-title":"HMB\u2010001 \u2010 A novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann thrombasthenia","volume":"6","author":"Ostergaard H","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"23","key":"e_1_2_10_65_1","first-page":"2891","article-title":"Efficacy of platelet\u2010inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models","volume":"141","author":"Roullet S","year":"2023","journal-title":"Blood"},{"key":"e_1_2_10_66_1","article-title":"KB\u2010V13A12, a novel nanobody\u2010based therapeutic molecular for the treatment of von Willebrand disease","author":"Peyron I","year":"2023","journal-title":"Int Soc Thromb Haemost"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010716"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13551"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33796-7"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.01.014"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T03:06:32Z","timestamp":1713668792000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":69,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/hae.14970"],"URL":"https:\/\/doi.org\/10.1111\/hae.14970","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"assertion":[{"value":"2024-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}